- Home
- GPOR vs MIRM Comparison
GPOR vs MIRM Comparison
Compare GPOR & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GPOR | MIRM |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 7.2B |
| IPO Year | 1998 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GPOR | MIRM |
|---|---|---|
| Price | $155.91 | $89.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $233.33 | $119.85 |
| AVG Volume (30 Days) | 223.9K | ★ 504.0K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 245.92 | 74.59 |
| EPS | ★ 13.82 | N/A |
| Revenue | ★ $1,422,583,000.00 | $19,138,000.00 |
| Revenue This Year | $18.35 | $26.22 |
| Revenue Next Year | $6.04 | $22.04 |
| P/E Ratio | $11.72 | ★ N/A |
| Revenue Growth | ★ 48.47 | N/A |
| 52 Week Low | $149.18 | $63.23 |
| 52 Week High | $225.78 | $130.00 |
Technical Indicators
Market Signals| Indicator | GPOR | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 34.48 | 35.30 |
| Support Level | $149.18 | $88.08 |
| Resistance Level | $173.70 | $98.03 |
| Average True Range (ATR) | 5.19 | 3.98 |
| MACD | -2.09 | -0.60 |
| Stochastic Oscillator | 4.02 | 14.55 |
Price Performance
Historical ComparisonAbout GPOR Gulfport Energy Corporation
Gulfport Energy Corp is an independent natural gas-weighted exploration and production company focused on the exploration, acquisition, and production of natural gas, crude oil, and natural gas liquids, with assets located in the Appalachia and Anadarko basins in the United States. The principal properties of the company are located in eastern Ohio, targeting the Utica and Marcellus, and in central Oklahoma, targeting the SCOOP Woodford and Springer formations.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.